Journal article · 2024

Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.

Arndt Vogel, Stephen Lam Chan, Zhenggang Ren, Yuxian Bai, Shanzhi Gu, Xiaoyan Lin, Zhendong Chen, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Alexander Valerievich Sultanbaev and 9 more

Journal of Clinical Oncology, 42(16_suppl), 4110 · Published 1 June 2024 · DOI 10.1200/jco.2024.42.16_suppl.4110

View at the publisherCite this paper

In brief

“Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.” is a 2024 journal article by Arndt Vogel and 20 co-authors, published in Journal of Clinical Oncology. OpenAlex counts 39 citations as of 21 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
39
Most cited in
2025 (26)
Authors
21

Abstract

4110 Background: The phase 3 CARES-310 trial is the first to demonstrate significant progression-free survival (PFS) and overall survival (OS) benefits with immunotherapy plus an anti-angiogenic tyrosine kinase inhibitor (TKI) over standard TKI as first-line treatment for uHCC. In the primary analysis of PFS (data cut-off [DCO], May. 10, 2021) and interim analysis of OS… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Vogel, A., Chan, S. L., Ren, Z., Bai, Y., Gu, S., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., Hu, X., Sultanbaev, A. V., Pazgan−Simon, M., Pisetska, M., Nip, T. K., Zhang, H., Du, J., Cheng, A., Kaseb, A. O., . . . CARES-310 Study Group. (2024). Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study. Journal of Clinical Oncology, 42(16_suppl), 4110. https://doi.org/10.1200/jco.2024.42.16_suppl.4110

MLA 9

Vogel, Arndt, et al. “Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.” Journal of Clinical Oncology, vol. 42, no. 16_suppl, 2024, p. 4110. https://doi.org/10.1200/jco.2024.42.16_suppl.4110.

Chicago

Vogel, Arndt, Stephen Lam Chan, Zhenggang Ren, Yuxian Bai, Shanzhi Gu, Xiaoyan Lin, Zhendong Chen, et al. 2024. “Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.” Journal of Clinical Oncology 42 (16_suppl): 4110. https://doi.org/10.1200/jco.2024.42.16_suppl.4110.

Harvard

Vogel, A. et al. (2024) ‘Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.’, Journal of Clinical Oncology, 42(16_suppl), p. 4110. doi:10.1200/jco.2024.42.16_suppl.4110.

IEEE

A. Vogel et al., “Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.,” Journal of Clinical Oncology, vol. 42, no. 16_suppl, p. 4110, 2024, doi: 10.1200/jco.2024.42.16_suppl.4110.

BibTeX

@article{vogel2024camrelizumab,
  title     = {{Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.}},
  author    = {Vogel, Arndt and Chan, Stephen Lam and Ren, Zhenggang and Bai, Yuxian and Gu, Shanzhi and Lin, Xiaoyan and Chen, Zhendong and Jia, Weidong and Jin, Yongdong and Guo, Yabing and Hu, Xiaohua and Sultanbaev, Alexander Valerievich and Pazgan−Simon, Monika and Pisetska, Margaryta and Nip, Tsz Keung and Zhang, Haisong and Du, Jinghua and Cheng, Ann‐Lii and Kaseb, Ahmed Omar and Qin, Shukui and CARES-310 Study Group},
  journal   = {Journal of Clinical Oncology},
  year      = {2024},
  volume    = {42},
  number    = {16_suppl},
  pages     = {4110},
  doi       = {10.1200/jco.2024.42.16_suppl.4110},
  url       = {https://doi.org/10.1200/jco.2024.42.16_suppl.4110}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202455
20252626
202688

Topic and keywords

Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis

  • camrelizumab
  • apatinib
  • sorafenib
  • unresectable hepatocellular carcinoma
  • first-line therapy
  • anti-PD-1 therapy
  • VEGFR-2 inhibitors
  • overall survival

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Vogel, A., Chan, S. L., Ren, Z., Bai, Y., Gu, S., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., Hu, X., Sultanbaev, A. V., Pazgan−Simon, M., Pisetska, M., Nip, T. K., Zhang, H., Du, J., Cheng, A., Kaseb, A. O., . . . CARES-310 Study Group. (2024). Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study. Journal of Clinical Oncology, 42(16_suppl), 4110. https://doi.org/10.1200/jco.2024.42.16_suppl.4110

How many times has this paper been cited?

39 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Arndt Vogel, Stephen Lam Chan, Zhenggang Ren, Yuxian Bai, Shanzhi Gu, Xiaoyan Lin, Zhendong Chen, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Alexander Valerievich Sultanbaev and 9 more.

What is the DOI of this paper?

10.1200/jco.2024.42.16_suppl.4110, permanently at https://doi.org/10.1200/jco.2024.42.16_suppl.4110. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.